Prof. Dr. Lars Lindner is a medical oncologist specializing in sarcoma, regional hyperthermia, and liposomal therapies. He serves as Senior Consultant in Hematology and Oncology and heads both the Sarcoma Center and the Hyperthermia Unit at the University Hospital of Ludwig Maximilian University (LMU) Munich. He holds leading positions in several national and international organizations, including the European Society of Hyperthermic Oncology, the AIO Sarcoma and GIST Working Group, and the Bavarian Cancer Research Center (BZKF) Sarcoma Study Group. As co-founder of Thermosome, he and his team were the first to successfully evaluate temperature-sensitive liposomal doxorubicin in combination with regional deep hyperthermia in a Phase I clinical trial for patients with sarcoma. In 2026, he received the Hahn Award in recognition of his contributions to the field.